ACTUATE THERAPEUTICS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
1751 RIVER RUN, FORT WORTH, TX, 76107
Mailing Address
1751 RIVER RUN, FORT WORTH, TX, 76107
Phone
847-986-4190
Fiscal Year End
1231
EIN
473044785
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| DEF 14A Definitive proxy statement | April 6, 2026 | View on SEC |
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 10-K Annual financial report | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
| 8-K Current report of material events | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | January 7, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | December 17, 2025 | View on SEC |
| 8-K Current report of material events | November 28, 2025 | View on SEC |
Annual Reports
10-K
March 26, 2026
- Clinical-stage biotech focused on the single drug candidate elraglusib.
- Successfully completed IPO and follow-on offerings to fund operations through late 2026.
Insider Trading
SELL
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.